Optimizing Graft Selection in Glaucoma Surgery: A Comparative Study of Sclera, Pericardium, and Corneal Tissue

Conditions

• Glaucoma

Eligibility Criteria

Sex

ALL

Age

18 Years - 110 Years

Healthy Volunteers

Not accepted

Interventions

• MicroShunt with Scleral Patch Graft — PROCEDURE
  Placement of PreserFlo MicroShunt with donor scleral patch graft to cover the tube.
• MicroShunt with Corneal Patch Graft — PROCEDURE
  Placement of PreserFlo MicroShunt with donor corneal patch graft to cover the tube.
• MicroShunt with Pericardial Patch Graft — PROCEDURE
  Placement of PreserFlo MicroShunt with pericardial patch graft to cover the tube.

Study Details

Glaucoma refers to a group of progressive optic neuropathies that lead to permanent vision loss. Glaucoma is the leading cause of irreversible blindness globally. In 2020, it was estimated to affect 76 million individuals worldwide, with projections indicating this number will rise to 111.8 million by 2040. In Canada, glaucoma affects an estimated 2.7-7.5% of individuals over the age of 50, contributing substantially to the national disease burden. This condition is linked to damage of the optic nerve due to elevated intraocular pressure (IOP; raised eye pressure), which results in the loss of retinal ganglion cells. Therefore, most of the treatments are guided towards reducing the IOP either via using laser, medications or surgery. Glaucoma surgery is typically reserved for cases where IOP remains uncontrolled while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery. The goal of many glaucoma surgeries is to divert aqueous humor from the anterior chamber to the subconjunctival space, therefore reducing intraocular pressure. The device used for this purpose are the PRESERFLO™ MicroShunt (Glaukos Corporation, Laguna Hills, CA, USA) (the documents will interchangeably use terms "stent" and "shunt" to refer to these devices in the text below). The device is implanted using the ab externo approach to channel fluid from the anterior chamber to the subconjunctival/subtenon space. To reduce postoperative fibrosis and inhibit fibroblast activity that could obstruct flow and lead to device failure, 5-fluorouracil (5-FU) or mitomycin C (MMC) are administered. Additionally, a double-layered closure of conjunctiva and Tenon's is performed to minimize Tenon's migration and blockage of tenon the stents. Despite these measures, stent encapsulation and failure are still too common requiring revisions and bleb needling in 2-20% of cases within the first 12 months of follow-up. This project will involve a series of studies evaluating graft selection in PreserFlo MicroShunt implantation, focusing on donor sclera, cornea, and pericardium as patch graft materials. First, the investigators will conduct a prospective, randomized study comparing clinical outcomes between these graft types. Outcomes of interest will include surgical success rates, post-operative hypotony, tube erosion, conjunctival complications, infection, and overall device longevity. Donor sclera has long been used as a patch graft in glaucoma drainage device surgery and is associated with low erosion rates and reliable long-term results. Corneal tissue is increasingly used due to its transparency and availability through eye banks, with demonstrated safety in ocular surface reconstruction and tube coverage. Pericardium is another durable, biocompatible option, historically applied in both cardiovascular and ocular surgery, and has shown effectiveness as a patch graft in glaucoma drainage implants. This comparison will extend to both primary implantation and revision surgeries, recognizing the high clinical relevance of graft performance in complex cases. Building on these results, the investigators will then perform a cost-effectiveness analysis of graft strategies, incorporating surgical time, post-operative management, complication rates, and need for re-operation. An economic model will be developed to evaluate costs and resource utilization associated with each material, providing valuable data for policy and surgical decision-making. Finally, the investigators will conduct a patient-reported outcome (PRO) study to assess patient comfort and satisfaction with different grafts. Surveys will evaluate domains such as foreign body sensation, cosmesis, and overall satisfaction at key time points (immediate post-operative period, 1 week, 3 weeks, and 3 months). These results will highlight the patient perspective, an often underrepresented but critical factor in surgical innovation. Together, these studies will comprehensively assess graft selection from surgical, economic, and patient-centered perspectives, informing evidence-based practice in glaucoma care.

Key Dates

First listed

Dec 16, 2025

Start date

May 1, 2026

Status verified

Mar 2026

Primary completion

Oct 30, 2027

Completion

Dec 30, 2027

Study Design

Enrollment

180 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: PreserFlo with Donor Scleral Patch Graft
  Participants undergo PreserFlo MicroShunt implantation with a donor scleral patch graft covering the tube. Standard perioperative care (e.g., MMC/5-FU per site protocol) and scheduled follow-up (day 1; week 1-2; months 1, 3, 6, 9, 12). Outcomes include IOP, hypotony, tube erosion, conjunctival complications, infection, reoperations, device longevity, patient-reported comfort/cosmesis, and resource use. Primary and revision cases are included per stratified randomization.
• Experimental: PreserFlo with Corneal Patch Graft
  Participants undergo PreserFlo MicroShunt implantation with a donor corneal patch graft covering the tube. Standard perioperative care and identical follow-up schedule. Outcomes as above: IOP control, complications (including erosion and hypotony), reoperations, longevity, patient-reported outcomes, and resource use. Primary and revision cases are included per stratified randomization.
• Experimental: PreserFlo with Pericardial Patch Graft
  Participants undergo PreserFlo MicroShunt implantation with a pericardial patch graft covering the tube. Standard perioperative care and identical follow-up schedule. Outcomes as above: IOP control, complication profile, reoperations, longevity, patient-reported outcomes, and resource use. Primary and revision cases are included per stratified randomization.

Primary Outcome Measure

Mean Change in Intraocular Pressure (IOP) from Baseline to 12 Months [ Time Frame: 12 months ]

Central Contacts

• Paige Campbell, MD
  14039695473
  [email protected]

Find similar trials

Related Studies

• Novel Glaucoma Diagnostics
  Recruiting · Wills Eye · Philadelphia, Pennsylvania
• Stem Cell Ophthalmology Treatment Study II
  Recruiting · MD Stem Cells · Westport, Connecticut
• Village-Integrated Eye Worker Trial II
  Recruiting · University of California, San Francisco · San Francisco, California
• Pilocarpine Use After Kahook Goniotomy
  PHASE3 · Recruiting · Montefiore Medical Center · The Bronx, New York